Category: Health

Vitamin D supplements may reduce the risk of long COVID symptoms, such as fatigue and brain fog, according to a recent study conducted by researchers at Mass General Brigham.

A new study suggests that vitamin D supplements could play a role in alleviating long COVID symptoms, which persist after the initial infection. Researchers at Mass General Brigham investigated whether high doses of vitamin D could affect COVID-19 outcomes, particularly the risk of developing long COVID, a condition characterized by lingering symptoms such as fatigue, shortness of breath, and brain fog. The findings were published in The Journal of Nutrition.

The randomized clinical trial involved 1,747 adults who had recently tested positive for COVID-19, along with 277 members of their households. Participants were assigned to receive either vitamin D3 supplements or a placebo for a duration of four weeks.

Dr. JoAnn Manson, the senior author of the study and a physician at Mass General Brigham, highlighted the potential benefits of vitamin D supplementation for long-term symptoms. “A key takeaway is that vitamin D supplementation looks promising for reducing the risk of developing long COVID but does not appear to affect the severity of the acute infection,” Manson stated.

While the study found that vitamin D supplementation did not significantly alter short-term outcomes, such as symptom severity or the need for hospital visits, a closer examination of participants who adhered to the supplement regimen revealed a noteworthy difference in lingering symptoms. Approximately 21% of those who took vitamin D reported at least one ongoing symptom eight weeks after infection, compared to 25% of participants who received a placebo.

“There’s been tremendous interest in whether vitamin D supplements can be of benefit in COVID, and this is one of the largest and most rigorous randomized trials on the subject,” Manson remarked in a press release. “While we didn’t find that high-dose vitamin D reduced COVID severity or hospitalizations, we observed a promising signal for long COVID that merits additional research,” she added.

Manson explained that vitamin D may influence longer-term complications due to its role in regulating inflammation within the body. However, the researchers acknowledged several limitations in the trial. The study had to be conducted remotely during the pandemic, and participants began taking vitamin D several days after their COVID diagnosis.

Ideally, Manson noted, supplementation should commence before infection or immediately following diagnosis. She emphasized the need for larger studies to confirm whether vitamin D could effectively reduce the risk or severity of long COVID symptoms.

Researchers are planning additional trials to further explore the potential of vitamin D supplementation in treating individuals already experiencing long COVID.

These findings provide a promising avenue for future research and may offer hope for those grappling with the long-term effects of COVID-19, according to Fox News.

A groundbreaking blood test could identify dementia risk in women up to 25 years before symptoms appear, according to research from the University of California San Diego.

Researchers from the University of California San Diego have developed a blood test that may determine a woman’s risk of developing dementia as early as 25 years before any symptoms manifest. This promising finding centers on a specific biomarker protein associated with the early pathological processes of Alzheimer’s disease, known as phosphorylated tau 217 (p-tau217).

The study analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study, conducted in the late 1990s. The participants, aged between 65 and 79, exhibited no signs of cognitive decline at the study’s outset. Over a follow-up period of up to 25 years, researchers found a strong association between elevated levels of p-tau217 and future instances of mild cognitive impairment and dementia.

Women with higher levels of p-tau217 at the beginning of the study were significantly more likely to develop dementia later on. The findings were published in JAMA Network Open, highlighting the potential for early detection of dementia risk through a simple blood test.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” said Aladdin H. Shadyab, the study’s first author and an associate professor of public health and medicine at UC San Diego. “Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin.”

This early detection could pave the way for preventive strategies and targeted monitoring, allowing for interventions before memory issues disrupt daily life. Shadyab emphasized that as research progresses, these biomarkers could help pinpoint individuals at the greatest risk and inform strategies to delay or prevent dementia.

However, the relationship between p-tau217 levels and dementia risk was not uniform across all demographics. The study indicated that women over 70 with elevated p-tau217 levels experienced poorer cognitive outcomes compared to their younger counterparts. Additionally, those with the APOE ε4 gene, a known risk factor for Alzheimer’s disease, also showed a stronger correlation between p-tau217 levels and cognitive decline.

Interestingly, the study revealed that p-tau217 was a more significant predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy, compared to those who received a placebo. This finding suggests that hormonal factors may play a role in the relationship between p-tau217 levels and dementia risk.

Senior author Linda K. McEvoy, a senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, noted the advantages of blood-based biomarkers like p-tau217. “Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” she explained. “This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Despite the promising nature of these findings, Shadyab cautioned that blood tests for Alzheimer’s disease are still under investigation and are not yet recommended for routine screening in asymptomatic individuals. Further research is necessary before this approach can be considered for clinical use prior to the onset of cognitive symptoms.

Future studies should explore how various factors, including genetics, hormone therapy, and age-related medical conditions, may interact with plasma p-tau217 levels. Shadyab also pointed out that the study focused exclusively on older women, indicating that the findings may not be applicable to men or younger populations. Additionally, the research examined overall dementia outcomes rather than specific subtypes, such as Alzheimer’s disease.

As the understanding of dementia risk factors evolves, the potential for early detection through blood tests like p-tau217 may revolutionize the approach to managing and preventing this debilitating condition.

According to Fox News Digital, the implications of this research could significantly impact future dementia prevention strategies.

Compounds in cannabis, particularly cannabidiol (CBD) and cannabigerol (CBG), may offer new treatment options for metabolic dysfunction-associated steatotic liver disease, a common chronic liver condition affecting many adults worldwide.

Research from the Hebrew University of Jerusalem suggests that compounds found in cannabis could pave the way for innovative treatments for the world’s most prevalent chronic liver disorder. The study, published in the British Journal of Pharmacology, highlights the potential of cannabidiol (CBD) and cannabigerol (CBG) in reducing liver fat and enhancing metabolic health in experimental models.

CBD is the more extensively researched non-intoxicating cannabinoid, while CBG serves as a precursor cannabinoid from which CBD is derived. Unlike THC, the primary psychoactive component of cannabis, both CBD and CBG do not induce a “high,” making them promising candidates for long-term medical applications.

Metabolic dysfunction-associated steatotic liver disease (MASLD) currently impacts approximately one-third of the global adult population, as indicated by health data. This condition is closely associated with obesity and insulin resistance, yet there are few approved pharmaceutical treatments available. Consequently, patients often rely on challenging lifestyle changes to manage their condition.

Lead study author Joseph Tam, director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University, stated, “Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function.”

The research emphasizes a process known as “metabolic remodeling,” where the cannabis compounds create a “backup battery” for the liver by increasing levels of phosphocreatine, a high-energy molecule stored in muscle cells. This energy reserve enables the liver to function more effectively under the stress of a high-fat diet, an unexpected finding noted by the research team.

Additionally, the study revealed that CBD and CBG restored the activity of “cellular cleaning crews,” known as cathepsins. These enzymes operate within the cell’s recycling centers to break down harmful fats and waste. As a result, the liver became more adept at clearing dangerous lipids, including triglycerides and ceramides, which are known to cause inflammation.

While both CBD and CBG demonstrated effectiveness, CBG yielded more pronounced results in specific areas, such as reducing total body fat mass, lowering “bad” LDL cholesterol, and improving insulin sensitivity. The researchers believe this study opens new avenues for utilizing plant-based compounds to treat metabolic diseases by focusing on cellular energy management and waste disposal.

Despite these promising findings, the research team cautioned that the study was conducted in a controlled experimental setting. Further clinical trials are essential to ascertain the appropriate application of these compounds for human patients.

Recent studies have also raised concerns regarding the use of cannabis as a medical treatment. A major analysis published in JAMA examined over 2,500 scientific papers from the past 15 years, including reviews, clinical trials, and guidelines related to medical marijuana. This review underscored significant discrepancies between public perception and scientific evidence regarding the effectiveness of cannabis for various medical conditions.

The researchers concluded that only a limited number of conditions have clear, well-established benefits from cannabinoid therapies supported by high-quality clinical data. “Whenever a substance is widely used, there is likely to be a very wide set of outcomes,” noted Dr. Alex Dimitriu, who is double board-certified in psychiatry and sleep medicine. He emphasized that this study illustrates the reality that cannabis is not a universal remedy.

The strongest evidence currently supports FDA-approved cannabinoid medications for treating specific conditions, including appetite loss related to HIV/AIDS, chemotherapy-induced nausea and vomiting, and certain severe pediatric seizure disorders.

Individuals interested in exploring marijuana for medical purposes are encouraged to consult with a healthcare provider to discuss potential risks and benefits, ensuring informed decision-making regarding their health.

According to Fox News, the implications of this research could significantly impact the future treatment landscape for liver diseases.

Recent studies indicate that GLP-1 drugs, including Ozempic and Wegovy, may increase fracture risk and osteoporosis in older adults with Type 2 diabetes, prompting calls for closer monitoring of bone health.

A new study suggests that GLP-1 medications, such as Ozempic and Wegovy, may elevate the risk of fractures by 11% in adults aged 65 and older who have Type 2 diabetes, compared to those using other diabetes treatments.

These GLP-1 drugs have revolutionized the management of Type 2 diabetes and obesity, but recent findings indicate that healthcare providers should be more vigilant regarding bone health in older patients prescribed these medications. A study published in February in the Journal of Clinical Endocrinology & Metabolism revealed that older adults with Type 2 diabetes who began using GLP-1 medications experienced a statistically significant increase in the risk of fragility fractures.

Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel and the study’s lead author, emphasized that while an 11% increase may seem modest, it is significant for a vulnerable population. “Both older age and Type 2 diabetes are independent risk factors for fragility fractures,” she stated. “This is a population that deserves special attention.”

Fragility fractures are typically caused by minor falls or routine activities and are often associated with osteoporosis. Such fractures can lead to hospitalization, loss of independence, and even increased mortality among older adults, according to Dr. Kasher Meron.

The study monitored over 46,000 adults aged 65 and older for nearly three years. After making necessary adjustments, researchers found that those using GLP-1 medications had a modest but statistically significant increase in fracture risk.

Previous studies involving younger patients using older GLP-1 medications did not indicate an increased fracture risk. However, the newer and more potent versions are now commonly prescribed to older adults, which alters the risk landscape. “In older adults treated with contemporary medications, the fracture risk picture looks different and warrants close attention,” Dr. Kasher Meron noted.

It is important to highlight that the study was observational, indicating an association rather than causation. Researchers could not ascertain whether the increased risk was due to weight loss, dietary changes, muscle loss, or a direct effect on bone health.

Despite these findings, Dr. Kasher Meron advocates for assessing bone health before initiating GLP-1 medications in older patients rather than treating it as an afterthought. The study’s results coincide with additional research presented at the American Academy of Orthopaedic Surgeons’ annual meeting, which raised further concerns regarding bone health.

In an analysis of over 146,000 adults with obesity and Type 2 diabetes, those using GLP-1 medications were found to have a 29% higher relative risk of developing osteoporosis over five years compared to nonusers. Additionally, rates of gout were slightly elevated, affecting 7.4% of GLP-1 users versus 6.6% of nonusers, representing a 12% relative increase. Osteomalacia, a condition characterized by softening of the bones, was rare but occurred approximately twice as often in GLP-1 users, according to the study, which has not yet undergone peer review.

Experts suggest several mechanisms may contribute to these findings. GLP-1 medications suppress appetite and can lead to rapid weight loss, which is known to reduce bone density. This reduction occurs partly because less mechanical load is placed on the skeleton. Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, likened this phenomenon to astronauts experiencing low bone density after extended periods in a zero-gravity environment.

Moreover, a decrease in caloric intake may result in lower consumption of calcium, vitamin D, and protein—nutrients essential for maintaining bone strength. Rapid weight loss can also temporarily elevate uric acid levels, a byproduct of tissue breakdown, potentially explaining the rise in gout cases.

Despite these concerns, experts caution against discouraging the appropriate use of GLP-1 medications, which have demonstrated significant benefits for blood sugar control, weight loss, and cardiovascular risk reduction. In addition to bone density screenings, experts recommend that patients ensure adequate nutrition and engage in resistance training to help preserve muscle and bone during weight loss.

A spokesperson for Novo Nordisk, the manufacturer of GLP-1 medications, stated that the company prioritizes patient safety and collaborates closely with the U.S. Food and Drug Administration (FDA). Liz Skrbkova, head of U.S. media relations for Novo Nordisk, emphasized that the known risks and benefits of these drugs are reflected in the current FDA-approved labeling. She noted that semaglutide, one of the GLP-1 medications, has shown cardiovascular, kidney, and liver benefits when used under medical supervision.

“Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors,” Skrbkova added.

These findings underscore the need for healthcare providers to closely monitor bone health in older adults prescribed GLP-1 medications, ensuring that the benefits of these treatments are balanced with potential risks.

According to Fox News Digital, the implications of these studies are significant for the management of diabetes and obesity in older populations.

New research suggests that GLP-1 weight-loss drugs may significantly reduce complications after heart attacks by improving blood flow to heart tissue.

Groundbreaking research indicates that a popular class of weight-loss drugs could play a crucial role in preventing life-threatening heart complications by reopening blocked blood vessels following heart attacks. The study, published this week in Nature Communications, was conducted by researchers from the University of Bristol and University College London.

The research identifies a biological signaling pathway involving the brain, gut, and heart, which may explain how GLP-1 drugs—medications that mimic the hormone glucagon-like peptide-1—help protect heart tissue from a condition known as “no-reflow.” This condition occurs when tiny blood vessels within the heart muscle remain constricted even after the main artery has been cleared during emergency treatment.

Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, highlighted the significance of the findings. “In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” she stated in a press release. “This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.” The lack of blood flow can increase the risk of heart failure and death within a year, but GLP-1 medications may offer a preventive solution.

The study reveals that when the GLP-1 hormone is released in the gut or administered as a medication, it sends signals to the brain. The brain, in turn, signals the heart to activate specific potassium channels in tiny cells known as pericytes. When these channels open, the pericytes relax, allowing small blood vessels, or capillaries, to widen and improve blood flow to the heart muscle.

Using animal models and cellular imaging, the researchers tracked how GLP-1 interacts with heart tissue. They discovered that when potassium channels were removed, the protective effects of the drugs on the heart were lost, confirming the channels’ critical role in this process.

The findings suggest that existing GLP-1 medications, which are already prescribed for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to minimize tissue damage.

However, the researchers acknowledged several limitations in their study, including its reliance on animal models. Clinical trials will be necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans. Moreover, while the study emphasizes the drug’s immediate benefits during a heart attack, it does not clarify whether long-term use of the medication provides any pre-existing level of protection.

This research was primarily funded by the British Heart Foundation, underscoring the potential implications for future heart attack treatments.

According to Fox News, the study opens new avenues for understanding how existing medications can be utilized to enhance heart health and reduce complications following cardiac events.

Researchers have discovered that levetiracetam, a decades-old seizure medication, may prevent the progression of Alzheimer’s disease if administered years before symptoms manifest.

A promising breakthrough in Alzheimer’s prevention has emerged from a recent study suggesting that levetiracetam, a medication traditionally used to treat seizures, may help halt the disease’s progression. Originally approved by the FDA in November 1999 under the brand name Keppra, levetiracetam is primarily prescribed for partial-onset seizures in adults, with its use later expanding to include children and various seizure types.

Researchers at Northwestern University have found that levetiracetam can prevent the formation of toxic amyloid beta peptides, which are small protein fragments commonly associated with Alzheimer’s disease. The study, published in Science Translational Medicine, revealed that the medication effectively inhibited the formation of amyloid-beta 42 in both animal models and cultured human neurons. This effect was also observed in post-mortem brain tissue from individuals with Down syndrome, a group at heightened risk for developing Alzheimer’s.

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid-beta 42 peptides and amyloid plaques,” said Jeffrey Savas, the study’s corresponding author and an associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine. “Our new results uncovered new biology while also opening doors for new drug targets.”

Savas explained that the brain is better equipped to avoid the pathways that produce toxic amyloid-beta 42 proteins during younger years. However, as individuals age, this ability diminishes. “This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he noted. This accumulation can lead to the formation of tau tangles—abnormal clumps of protein inside brain neurons—which can ultimately kill brain cells, trigger neuroinflammation, and result in dementia.

For levetiracetam to serve as an effective Alzheimer’s preventive, high-risk individuals would need to begin treatment “very, very early,” potentially up to 20 years before elevated levels of amyloid-beta 42 are detected. “You couldn’t take this when you already have dementia because the brain has already undergone a number of irreversible changes and a lot of cell death,” Savas cautioned.

The research team also analyzed existing clinical data to assess whether Alzheimer’s patients taking levetiracetam experienced a slower cognitive decline. They found that these patients had a “significant delay” in the time from cognitive decline to death compared to those not on the medication. “Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas stated.

Looking ahead, the research team aims to recruit individuals with genetic forms of Alzheimer’s for further testing. However, the study does have limitations, including its reliance on animal models and cultured cells, with no human trials conducted to date. As the study was observational, it cannot definitively prove that levetiracetam caused the prevention of toxic brain proteins.

Savas acknowledged that while levetiracetam shows promise, it is not without its drawbacks. The medication breaks down in the body relatively quickly, prompting the research team to work on developing a “better version” that would have a longer duration of action and more effectively target the mechanism responsible for preventing plaque production.

Common side effects of levetiracetam include drowsiness, weakness, dizziness, irritability, headache, loss of appetite, and nasal congestion. The medication has also been associated with potential mood and behavior changes, such as anxiety, depression, agitation, and aggression. In rare cases, it may lead to severe allergic reactions, skin reactions, blood disorders, and suicidal ideation.

Funding for this study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund. For further details, Fox News Digital reached out to both the drug manufacturer and the researchers for additional comments.

Experts caution individuals with diabetes to be vigilant about certain supplements that may adversely affect blood sugar levels and interact with medications.

Health experts are urging individuals with diabetes to exercise caution when considering dietary supplements, as some may pose significant risks by affecting blood sugar levels or interacting negatively with prescribed medications.

Surveys indicate that approximately 75% of U.S. adults have used dietary supplements, with 58% reporting usage within the past 30 days. However, experts emphasize that certain groups, particularly those with diabetes, should be particularly careful.

Dietary supplements encompass a wide range of products, including vitamins, minerals, herbs, amino acids, and probiotics, all designed to fill nutritional gaps and promote overall wellness. Some supplements target specific health functions, such as immune support, muscle recovery, and bone health.

Unlike prescription medications and over-the-counter drugs, dietary supplements are not typically approved by the Food and Drug Administration (FDA) before they hit the market. However, the FDA does regulate these products and can take action against those deemed unsafe or misbranded.

According to the National Institutes of Health (NIH), several supplements may pose serious health risks for individuals with diabetes. Dawn Menning, a registered dietitian and certified diabetes care and education specialist based in California, highlights St. John’s Wort as a supplement to avoid. While it is often marketed as a natural remedy for mild to moderate depression, it can interfere with diabetes medications by altering how the body metabolizes them.

“This can make medications less effective and complicate blood sugar management,” Menning explained. Although some claim that St. John’s Wort can help regulate blood sugar in individuals with type 2 diabetes, the evidence supporting this is limited and mixed.

Menning warns that combining this supplement with insulin or oral diabetes medications may increase the risk of hypoglycemia, a condition characterized by dangerously low blood sugar levels that can lead to dizziness, fatigue, and fainting.

Another supplement of concern is high-dose niacin, which is sometimes used to manage cholesterol levels. However, Menning cautions that it can significantly raise blood sugar levels, making it difficult to maintain an optimal A1c range.

Asian ginseng is often associated with increased energy, focus, and immune health. While it may offer some benefits for individuals with prediabetes and diabetes, there is evidence suggesting that it could lower blood sugar levels when taken alongside diabetes medications.

Jordan Hill, a registered dietitian with Top Nutrition Coaching in Colorado, advises against β-carotene supplementation for people with diabetes. The American Diabetes Association has linked this supplement to increased risks of lung cancer and cardiovascular mortality.

Cinnamon, frequently promoted for diabetes management and weight loss, has shown potential in reducing blood sugar and lowering insulin resistance. However, excessive consumption can lead to hypoglycemia, as well as liver damage due to a compound called coumarin found in cinnamon.

Oral aloe vera is another supplement that has gained popularity for its purported benefits for diabetes and weight loss. However, when combined with diabetes medications, it may cause blood sugar levels to drop too low, increasing the risk of hypoglycemia. Gastrointestinal side effects are also a concern with aloe vera.

Menning notes that for most supplements, there is insufficient evidence to support any beneficial effects on diabetes or its complications. The American Diabetes Standards of Care state that “without underlying deficiency, there are no benefits from herbal or nonherbal (i.e., vitamin or mineral) supplementation for people with diabetes.”

Furthermore, the American Association of Clinical Endocrinology advises caution with all unregulated nutritional supplements due to their inconsistent composition, quality, and potential for harm.

Experts recommend consulting with a healthcare provider before starting any supplement regimen to better understand how it may impact blood sugar levels, medications, or overall diabetes management.

For more information on the risks associated with dietary supplements for people with diabetes, refer to the National Institutes of Health.

A newly discovered virus within gut bacteria may be linked to an increased risk of colorectal cancer, offering new insights into the disease’s development, according to recent research.

Scientists in Denmark have identified a previously unknown virus residing in the gut bacterium Bacteroides fragilis, which may be associated with the development of colorectal cancer. The study, published in *Communications Medicine* earlier this month, reveals that patients diagnosed with colorectal cancer are approximately twice as likely to carry this virus compared to individuals without the disease.

Dr. Flemming Damgaard, PhD, from the Department of Clinical Microbiology at Odense University Hospital and the University of Southern Denmark, emphasized the significance of microorganisms in relation to human health. “These findings highlight the importance of the microorganisms in the gut and their relation to our health,” he stated. “If we want to understand the full picture, we need to look deep into their genetic material.”

For years, medical professionals have noted a higher prevalence of Bacteroides fragilis in colorectal cancer patients. However, since this bacterium is also commonly found in healthy individuals, the reasons for its harmful effects in certain cases remained unclear. This prompted researchers to investigate subtle genetic variations within the bacteria, leading to an unexpected discovery.

“We were very surprised to find a whole virus inside the bacteria from the colorectal cancer patients,” Damgaard remarked. “That was not something we expected when we started our study.”

The identified virus, classified as a bacteriophage, specifically infects bacteria rather than human cells. Notably, this viral type had not been documented prior to this research. The study involved analyzing stool samples from 877 individuals across Europe, the United States, and Asia, revealing that colorectal cancer patients were about twice as likely to carry traces of the virus compared to their cancer-free counterparts.

While the findings indicate a strong statistical association, researchers caution that the study does not establish a causal link between the virus and colorectal cancer. “The major limitation is that we still don’t know why the virus is linked to colorectal cancer,” co-author Ulrik Stenz Justesen explained. “But we are already continuing our research.”

The research team is currently conducting laboratory experiments and animal studies to explore whether the virus influences the behavior of Bacteroides fragilis in a manner that could contribute to cancer development.

Studies have shown that the human body is home to roughly as many microbial cells as human cells, highlighting the intricate relationship between microbes and overall health. “Our understanding of [microbial cells] is still in its infancy,” Damgaard noted. “There are many health-related discoveries to be made in the human microbiota.”

Colorectal cancer ranks among the leading causes of cancer-related deaths globally, according to the World Health Organization. The disease has gained increased visibility due to the deaths of several high-profile individuals, including James Van Der Beek, Catherine O’Hara, Kirstie Alley, Pelé, and Chadwick Boseman, underscoring its impact across various age groups.

While diet and lifestyle factors are significant contributors to colorectal cancer risk, researchers believe that gut bacteria may also play a crucial role. Current screening methods for colorectal cancer include stool tests that detect hidden blood and colonoscopies. In the future, researchers suggest it may be possible to test stool samples for viral markers similar to those identified in this study.

The researchers pointed to cervical cancer as an example of how recognizing a viral cause can enhance prevention efforts. Following the link between HPV and cervical cancer, vaccination programs have significantly reduced new cases. Although it is premature to draw direct comparisons, the researchers remain hopeful that colorectal cancer could follow a similar trajectory if a definitive viral role is established.

“It is too early to act,” Damgaard cautioned. “We have a lot of hope, and that is what we want people to have at this point,” he concluded.

According to Fox News Digital, this research opens new avenues for understanding the complexities of colorectal cancer and the potential role of viruses within the gut microbiome.

James Van Der Beek’s death underscores a troubling rise in colon cancer cases among younger adults, prompting urgent calls for increased awareness and earlier screening.

Following the death of actor James Van Der Beek after a two-and-a-half-year battle with colon cancer, health experts are sounding the alarm about the increasing prevalence of this disease among younger individuals. The star of “Dawson’s Creek” publicly shared his stage 3 colon cancer diagnosis in November 2024, although he was officially diagnosed in August 2023 after undergoing a colonoscopy.

In an August 2025 interview with Healthline, Van Der Beek revealed that the first warning sign of his colon cancer was a change in his bowel movements, which he initially attributed to his coffee consumption. “Before my diagnosis, I didn’t know much about colorectal cancer,” he admitted. “I didn’t even realize the screening age had dropped to 45; I thought it was still 50.”

Recent research has highlighted a concerning trend: colorectal cancer (CRC) has become the leading cause of cancer-related death among men and women aged 50 and younger, according to the American Cancer Society. This marks a significant shift from the 1990s, when CRC was the fifth deadliest cancer in this age group. While overall cancer deaths have declined by approximately 44% since 1990, CRC is the only major cancer that has seen an increase in mortality rates for those under 50 during this time.

Dr. Aparna Parikh, medical director of the Center for Young Adult Colorectal Cancer at the Mass General Cancer Center, noted that the reasons behind this rise remain unclear. “Experts don’t entirely understand why cases are on the rise,” she explained. “But it seems to be an interplay of a person’s risk factors, overall makeup, and early exposures.” These exposures may include dietary habits, environmental factors, and even antibiotic use, along with lifestyle choices.

A recent study by the American Cancer Society found that long-term heavy drinking is associated with an increased risk of developing colorectal cancer. Other significant risk factors include family history of the disease, obesity, smoking, a diet high in red and processed meats, inflammatory bowel disease, and a personal or family history of polyps.

In a recent appearance on “America’s Newsroom,” Fox News senior medical analyst Dr. Marc Siegel discussed the rising incidence of CRC among younger adults. He highlighted the role of genetics and the consumption of ultraprocessed foods, citing a study from Mass General that indicates a diet high in such foods increases the likelihood of colon cancer by 45%. Additionally, a diet rich in processed meats, such as hot dogs, raises the risk by 30%, while a diet high in red meat increases the risk by 20%.

Experts emphasize that while colorectal cancer may not present symptoms in its early stages, certain signs should not be ignored. Dr. Eitan Friedman, Ph.D., an oncologist and founder of The Suzanne Levy-Gertner Oncogenetics Unit at the Sheba Medical Center in Israel, confirmed that changes in bowel habits are a primary red flag for colorectal cancer. Other symptoms include fatigue due to anemia, abdominal pain or discomfort, rectal bleeding, weakness, and unexplained weight loss.

Dr. Erica Barnell, Ph.D., a physician-scientist at Washington University School of Medicine and co-founder of Geneoscopy, noted that Van Der Beek’s experience of having no obvious symptoms is not uncommon. “Many colorectal cancers develop silently, without obvious symptoms,” she explained. “By the time symptoms appear, the disease may already be advanced.”

Early detection is crucial for improving outcomes in colorectal cancer cases. “Colonoscopy at age 45 onwards, at five- to ten-year intervals, has been shown to lead to early detection of polyps that have the potential to become malignant,” Dr. Friedman stated. “Removing these polyps can significantly minimize the risk of malignant transformation.”

Unfortunately, Dr. Barnell pointed out that screening compliance in the United States remains below national targets, with the most significant gaps found in rural, low-income, and minority communities. “Most people don’t like talking about bowel habits, but paying attention to changes can save your life,” she urged. “Screening gives us the chance to find problems early—often before you feel sick—and that can make all the difference.”

Dr. Siegel reiterated the importance of colonoscopies as the most effective method for screening CRC, especially when polyps are detected and removed before they can develop into cancer. The rising incidence of colorectal cancer among younger adults, as exemplified by Van Der Beek’s tragic story, serves as a stark reminder of the need for increased awareness and proactive health measures.

As the conversation around colorectal cancer continues to evolve, it is essential for individuals to stay informed about their health and the importance of early screening. According to the American Cancer Society, understanding risk factors and recognizing warning signs can be life-saving.